blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2691384

EP2691384 - (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES [Right-click to bookmark this link]
Former [2014/06](ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES
[2016/26]
StatusNo opposition filed within time limit
Status updated on  01.09.2017
Database last updated on 31.03.2026
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
MEI Pharma, Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130 / US
[2014/06]
Inventor(s)01 / BROWN, S., David
12 Sorrel Lane
San Carlos, CA 94070 / US
02 / MATTHEWS, David, J.
2 Balceta Avenue
San Francisco, CA 94127 / US
 [2014/06]
Representative(s)Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Schweigerstraße 2
81541 München / DE
[N/P]
Former [2016/43]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Former [2014/06]Jones Day
Rechtsanwälte, Attorneys-at-Law Patentanwälte Intellectual Property Prinzregentenstraße 11
80538 München / DE
Application number, filing date12711551.727.03.2012
[2016/43]
WO2012US30640
Priority number, dateUS201161468502P28.03.2011         Original published format: US 201161468502 P
US201161530859P02.09.2011         Original published format: US 201161530859 P
US201161560699P16.11.2011         Original published format: US 201161560699 P
[2014/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012135160
Date:04.10.2012
Language:EN
[2012/40]
Type: A1 Application with search report 
No.:EP2691384
Date:05.02.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 04.10.2012 takes the place of the publication of the European patent application.
[2014/06]
Type: B1 Patent specification 
No.:EP2691384
Date:26.10.2016
Language:EN
[2016/43]
Search report(s)International search report - published on:EP04.10.2012
ClassificationIPC:C07D401/04, C07D403/04, C07D403/14, C07D413/14, A61K31/53, A61K31/506, A61P35/00
[2014/06]
CPC:
A61K31/5377 (EP,US); C07D403/14 (EP,CN,KR,RU,US); C07D403/04 (EP,CN,KR,US);
A61K31/506 (KR); A61K31/53 (KR,RU); A61P1/00 (EP);
A61P1/04 (EP); A61P1/08 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (EP);
A61P13/12 (EP); A61P15/10 (EP); A61P17/00 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P25/20 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P27/06 (EP); A61P27/16 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/04 (EP);
A61P31/10 (EP); A61P31/18 (EP); A61P33/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/02 (EP); A61P9/04 (EP);
A61P9/10 (EP); A61P9/12 (EP); C07D401/04 (RU);
C07D401/14 (EP,CN,RU,US); C07D413/14 (EP,KR,RU,US); C12N9/1205 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:(ALPHA-SUBSTITUIERTE ARALKYLAMINO- UND HETEROARALKYLAMINO)-PYRIMIDINYL- UND 1,3,5-TRIAZINYL-BENZIMIDAZOLES, SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND DIESE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG PROLIFERATIVER ERKRANKUNGEN[2016/26]
English:(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES[2016/26]
French:(ARALKYLAMINO- ET HETEROARALKYLAMINO)-PYRIMIDINYL- ET 1,3,5-TRIAZINYL-BENZIMIDAZOLES SUBSTITUES SUR LA POSITION ALPHA, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET CES COMPOSES DESTINES A ETRE UTILISES DANS LE TRAITEMENT DES MALADIES PROLIFERATIVES[2016/26]
Former [2014/06](ALPHA-SUBSTITUIERTE ARALKYLAMINO- UND HETEROARYLALKYLAMINO)PYRIMIDINYL UND 1,3,5 -TRIAZINYL-BENZIMIDAZOLE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND DIESE VERBINDUNGEN ZUR VERWENDUNG FÜR DIE BEHANDLUNG VON PROLIFERATIVEN ERKRANKUNGEN
Former [2014/06](ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES
Former [2014/06](ARALKYLAMINO ET HÉTÉROARYLALKYLAMINO ALPHA-SUBSTITUÉS)PYRIMIDINYL- ET 1,3,5-TRIAZINYLBENZIMIDAZOLES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CEUX-CI ET CES COMPOSÉS POUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
Entry into regional phase30.09.2013National basic fee paid 
30.09.2013Designation fee(s) paid 
30.09.2013Examination fee paid 
Examination procedure30.09.2013Examination requested  [2014/06]
14.05.2014Amendment by applicant (claims and/or description)
03.11.2015Despatch of a communication from the examining division (Time limit: M04)
11.03.2016Reply to a communication from the examining division
22.03.2016Despatch of a communication from the examining division (Time limit: M02)
23.05.2016Reply to a communication from the examining division
07.06.2016Communication of intention to grant the patent
15.09.2016Fee for grant paid
15.09.2016Fee for publishing/printing paid
15.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.11.2015
Opposition(s)27.07.2017No opposition filed within time limit [2017/40]
Fees paidRenewal fee
25.03.2014Renewal fee patent year 03
10.03.2015Renewal fee patent year 04
10.03.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.03.2012
AL26.10.2016
CY26.10.2016
EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
MK26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
TR26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
[2020/34]
Former [2020/15]HU27.03.2012
CY26.10.2016
EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
MK26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
TR26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
Former [2019/51]HU27.03.2012
CY26.10.2016
EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
MK26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
Former [2019/46]HU27.03.2012
CY26.10.2016
EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
Former [2019/31]HU27.03.2012
EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
Former [2018/43]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
MT27.03.2017
Former [2018/10]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
LU27.03.2017
Former [2017/52]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
MC26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SI26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
Former [2017/38]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SK26.10.2016
SM26.10.2016
BG26.01.2017
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
Former [2017/37]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SK26.10.2016
SM26.10.2016
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
Former [2017/36]EE26.10.2016
FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
PL26.10.2016
RO26.10.2016
RS26.10.2016
SK26.10.2016
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
Former [2017/26]FI26.10.2016
HR26.10.2016
LT26.10.2016
LV26.10.2016
PL26.10.2016
RS26.10.2016
NO26.01.2017
GR27.01.2017
IS26.02.2017
PT27.02.2017
Former [2017/12]LV26.10.2016
Cited inby applicant  STEPHENS ET AL., CURR. OPIN. PHARMACOL., vol. 5, 2005, pages 357
   WALKER ET AL., MOL. CELL., vol. 6, 2000, pages 909
   FOUKAS; SHEPHERD, BIOCHEM. SOC. TRANS., vol. 32, 2004, pages 330
   SHEPHERD, ACTA PHYSIOL. SCAND., vol. 183, 2005, pages 3
   JACKSON ET AL., NAT. MED., vol. 11, 2005, pages 507
   BARBER ET AL., NAT. MED., vol. 11, 2005, pages 933
   CAMPS ET AL., NAT. MED., vol. 11, 2005, pages 936
   ROMMEL ET AL., NAT. REV., vol. 7, 2007, pages 191
   ITO ET AL., J. PHARM. EXP. THERAP., vol. 321, 2007, pages 1
   "Remington: The Science and Practice ofPharmacy, 21st Edition", 2005, LIPPINCOTT WILLIAMS & WILKINS
   ROWE ET AL.: "Handbook of Pharmaceutical Excipients,5th Edition", 2005, THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL ASSOCIATION
   "Handbook ofPhanrzaceutical Additives, 3rd Edition,", 2007, GOWER PUBLISHING COMPANY
   "Pharmaceutical Preformulation and Formulation, 2nd Edition,", 2009, CRC PRESS LLC
   FRY, BIOCHEM. BIOPHYS. ACTA, vol. 1226, 1994, pages 237 - 268
   VANHAESEBROECK; WATERFIELD, EXP. CELL. RES., vol. 253, 1999, pages 239 - 254
   FRY, BREAST CANCER RES., vol. 3, 2001, pages 304 - 312
   IKENOUE ET AL., CANCER RES., vol. 65, 2005, pages 4562 - 4567
   GYMNOPOULOS ET AL., PROC. NATL. ACAD. SCI., vol. 104, 2007, pages 5569 - 5574
   BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
   STAHL AND WERMUTH: "Handbook of Pharmaceutical Salts, Properties, and Use", 2002, WILEY-VCH AND VHCA
   HARPER, PROGRESS IN DRUG RESEARCH, vol. 4, 1962, pages 221 - 294
   MOROZOWICH ET AL.: "Design ofBiopharmaceutical Properties through Prodrugs and Analogs", 1977, APHA ACAD. PHARM. SCI.
   "Bioreversible Carriers in Drug in Drug Design, Theory and Application", 1987, APHA ACAD. PHARM. SCI.
   BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
   WANG ET AL., CURR. PHARM. DESIGN, vol. 5, 1999, pages 265 - 287
   PAULETTI ET AL., ADV. DRUG. DELIVERY REV., vol. 27, 1997, pages 235 - 256
   MIZEN ET AL., PHARM. BIOTECH., vol. 11, 1998, pages 345 - 365
   GAIGNAULT ET AL., PRACT. MED. CHEM., 1996, pages 671 - 696
   ASGHARNEJAD ET AL.: "Transport Processes in Pharmaceutical Systems", 2000, MARCELL DEKKER, pages: 185 - 218
   BALANT ET AL., EUR. J. DRUG METAB. PHARMACOKINET., vol. 15, 1990, pages 143 - 53
   BALIMANE; SINKO, ADV. DRUG DELIVERY REV., vol. 39, 1999, pages 183 - 209
   BROWNE, CLIN. NEUROPHARMACOL., vol. 20, 1997, pages 1 - 12
   BUNDGAARD, ARCH. PHARM. CHEM., vol. 86, 1979, pages 1 - 39
   BUNDGAARD, CONTROLLED DRUG DELIVERY, vol. 17, 1987, pages 179 - 96
   BUNDGAARD, ADV. DRUG DELIVERY REV., vol. 8, 1992, pages 1 - 38
   FLEISHER ET AL., ADV. DRUG DELIVERY REV., vol. 19, 1996, pages 115 - 130
   FLEISHER ET AL., METHODS ENZYMOL., vol. 112, 1985, pages 360 - 381
   FARQUHAR ET AL., J. PHARM. SCI., vol. 72, 1983, pages 324 - 325
   FREEMAN ET AL., J. CHEM. SOC., CHEM. COMMUN., 1991, pages 875 - 877
   FRIIS; BUNDGAARD, EUR. J. PHARM. SCI., vol. 4, 1996, pages 49 - 59
   GANGWAR ET AL., DES. BIOPHARM. PROP. PRODRUGS ANALOGS, 1977, pages 409 - 421
   NATHWANI; WOOD, DRUGS, vol. 45, 1993, pages 866 - 94
   SINHABABU; THAKKER, ADV. DRUG DELIVERY REV., vol. 19, 1996, pages 241 - 273
   STELLA ET AL., DRUGS, vol. 29, 1985, pages 455 - 73
   TAN ET AL., ADV. DRUG DELIVERY REV., vol. 39, 1999, pages 117 - 151
   TAYLOR, ADV. DRUG DELIVERY REV., vol. 19, 1996, pages 131 - 148
   VALENTINO; BORCHARDT, DRUG DISCOVERY TODAY, vol. 2, 1997, pages 148 - 155
   WIEBE; KNAUS, ADV. DRUG DELIVERY REV., vol. 39, 1999, pages 63 - 80
   WALLER ET AL., BR. J. CLIN. PHARMAC., vol. 28, 1989, pages 497 - 507
   RATHBONE ET AL.,: "Modified-Release Drug Delivery Technology, 2nd Edition,", 2008, MARCEL DEKKER, INC.
   TAKADA ET AL.: "Encyclopedia of Controlled Drug Delivery", vol. 2, 1999, WILEY
   SANTUS; BAKER, J. CONTROLLED RELEASE, vol. 35, 1995, pages 1 - 21
   VERMA ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 26, 2000, pages 695 - 708
   VERMA ET AL., J. CONTROLLED RELEASE, vol. 79, 2002, pages 7 - 27
   "Multiparticulate Oral Drug Delivery", 1994, MARCEL DEKKER
   "Pharmaceutical Pelletization Technology", 1989, MARCEL DEKKER
   FISHMAN ET AL.: "Medicine, 2d Ed.", 1985, J.B. LIPPINCOTT CO.
   MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC.
   "The Merck Manual", 1999
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.